“The EACH Coalition is dedicated to lowering drug costs for patients; however, we are concerned that price limits have little direct impact on patient costs and could ultimately limit patient […]
In response to the Maryland PDAB’s request for comments on their selection of six drugs for cost review, the EACH Coalition submitted comments to the board outlining the concerns of
In response to the Washington PDAB’s request for input on therapeutic alternatives, the EACH Coalition submitted a testimony urging the board to handle carefully any policies that might limit treatment
Following the decisions by the Colorado PDAB designating Cosentyx and Stelara as unaffordable to patients in Colorado, the EACH Coalition submitted comments to the board urging against proceeding with an
